TTOO - T2 Biosystems Inc Stock Price, Fair Value and News

$0.35+0.02 (+6.06%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TTOO Price Action

Last 7 days

-5.4%

Last 30 days

-23.9%

Last 90 days

-84.0%

Trailing 12 Months

-92.7%

TTOO RSI Chart

TTOO Valuation

Market Cap

7.4M

Price/Earnings (Trailing)

-0.17

Price/Sales (Trailing)

0.96

Price/Free Cashflow

-0.2

TTOO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TTOO Fundamentals

TTOO Revenue

Revenue (TTM)

7.7M

Rev. Growth (Yr)

34.85%

Rev. Growth (Qtr)

1.69%

TTOO Earnings

Earnings (TTM)

-43.0M

Earnings Growth (Yr)

34.41%

Earnings Growth (Qtr)

-12.88%

TTOO Profitability

Return on Equity

367.13%

Return on Assets

-237.55%

Free Cashflow Yield

-496.83%

TTOO Investor Care

Shares Dilution (1Y)

419.54%

Diluted EPS (TTM)

59.37

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	7.2M	7.2M	7.7M	0
2023	17.1M	13.2M	11.0M	7.2M
2022	28.3M	27.6M	23.8M	22.3M
2021	22.5M	26.7M	28.9M	28.1M
2020	9.1M	9.8M	13.4M	18.1M
2019	10.0M	7.8M	7.1M	8.3M
2018	6.0M	9.0M	10.4M	10.5M
2017	3.9M	3.9M	3.9M	4.7M
2016	3.7M	4.1M	4.2M	4.1M
2015	454.0K	927.0K	1.9M	2.8M
2014	0	0	0	385.0K
2013	0	101.3K	183.7K	266.0K
2012	0	0	0	19.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About T2 Biosystems Inc

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

CEO	Mr. John J. Sperzel III, B.Sc.
WEBSITE	t2biosystems.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	158

T2 Biosystems Inc Frequently Asked Questions

What is the ticker symbol for T2 Biosystems Inc? What does TTOO stand for in stocks?

TTOO is the stock ticker symbol of T2 Biosystems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of T2 Biosystems Inc (TTOO)?

As of Fri Dec 20 2024, market cap of T2 Biosystems Inc is 7.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTOO stock?

You can check TTOO's fair value in chart for subscribers.

Is T2 Biosystems Inc a good stock to buy?

The fair value guage provides a quick view whether TTOO is over valued or under valued. Whether T2 Biosystems Inc is cheap or expensive depends on the assumptions which impact T2 Biosystems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTOO.

What is T2 Biosystems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, TTOO's PE ratio (Price to Earnings) is -0.17 and Price to Sales (PS) ratio is 0.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTOO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on T2 Biosystems Inc's stock?

In the past 10 years, T2 Biosystems Inc has provided -0.712 (multiply by 100 for percentage) rate of return.